Latest News

• Upcoming webinar!        

  Mark your calendars for Wednesday, August 27, 2025 at 8:30 ET/5:30 PT! We will be having a fantastic webinar with Dr. Nicholas Butowski on "Integrative Medicine for Patients with Primary Brain Tumors" (This webinar was rescheduled from last month.) 

  
  
• Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ in Leptomeningeal Metastases        

  Good news from the Phase 1 ReSPECT-LM trial evaluating an investigational radiotherapeutic (REYOBIQ™) in patients with leptomeningeal metastases (LM) - a rare, aggressive complication in advanced cancers. Among 29 patients treated in escalating dose cohorts, there was a 76% radiographic response rate and 87% clinical response rate. A strong biological effect was also observed; patients had up to 100% reduction in tumor cells found in the cerebrospinal fluid, and five of seven patients with major tumor cell reductions survived at least one year, which is well above the typical 2-6 month median survival for LM.

  Across the first four dosing cohorts (20 patients),median survival was 9 months, which is an improvement over historical outcomes. Side effects were mostly mild (grade 1–2), and only two patients experienced serious dose-limiting toxicity (grade 4 cytopenia) at the highest dose levels. Based on this trial, the team has identified a recommended dose for a Phase 2 trial. These early results suggest REYOBIQ has the potential to become a much-needed targeted treatment option for LM.

  
  
• Phase 1/2a study on Lisavanbulin Published in Journal Cell Reports Medicine        

  A recently published Phase 1/2a study evaluated Lisavanbulin, an oral microtubule-targeting agent, in patients with recurrent glioblastoma (GBM) and other high-grade gliomas (HGGs). In the Phase 1 trial, 28 patients received daily Lisavanbulin at doses up to 30 mg. Among them, one patient had a confirmed complete response (CR) and one had a confirmed partial response (PR) with 94% tumor shrinkage; both remained on therapy for over four years. An additional seven patients had stable disease, yielding a disease control rate (DCR) of 32.1%. However, median progression-free survival (PFS) was just 1.6 months, and only 11.2% of patients remained event-free at 12 months.

  In the Phase 2a expansion, 13 patients with recurrent GBM were pre-selected based on EB1 protein expression, a potential biomarker of response. Of nine with measurable disease, one patient had a durable PR and four had stable disease, for a DCR of 55.6%. Overall, the 12-month event-free survival was 32.5%, and 12-month overall survival was 55.6%, but the study did not meet its pre-specified efficacy threshold and was closed to further recruitment. Follow-up studies are planned to investigate why a small subset of patients had such exceptional and durable responses, with a focus on refining EB1 as a predictive biomarker to better identify likely responders.

  
  
• Social Security makes a big change to eligibility rules        

  The Social Security Administration has added Grade III meningioma to its Compassionate Allowances List (CAL), which will make it faster and easier for patients with this type of brain tumor to access disability benefits. Normally, applying for Social Security Disability Insurance (SSDI) can take months or even years, but inclusion on the CAL means that applications will be fast-tracked with minimal documentation and quicker decisions. This is an important advancement for patients and families facing the challenges of high-grade meningioma, helping them get financial support more efficiently.